Answers are grounded in this paper and cite their sources.
Shows fermented milk with Lactococcus lactis modulates gut microbiota and increases short-chain fatty acids in hypertensive rats, suggesting an antihypertensive effect via antioxidant status.
The aim of this study was to determine the effect of milk fermented with Lactococcus lactis NRRL B-50571 (FM-571) on gut microbiota (GM) of spontaneously hypertensive rats (SHRs), and its correlation with blood pressure (BP) short-chain-fatty acids (SCFAs) in feces, and antioxidant status in the plasma. Results showed that FM-571 increased ( p < 0.05) diversity and reduced Firmicutes/Bacteroidetes ratio in GM. Moreover, FM-571 increased abundance ( p < 0.05) of SCFA-producing bacteria Prevotellaceae (6.66 ± 3.29% and 7.29 ± 3.67%), Lachnospiraceae (21.38 ± 2.81% and 24.01 ± 12.32%), and Ruminococcaceae (21.82 ± 1.35 and 5.85 ± 0.3%) in feces and gut microbiota, respectively. Also, SCFAs in feces were higher ( p < 0.05) in SHR treated with FM-571 and were negatively correlated to BP ( p < 0.05). Additionally, Verrucomicrobiota, Acidoaminococcaceae, and Akkermansiaceae showed negative correlations with BP and oxidative stress index ( p < 0.05) and positive correlations with the activity of antioxidant enzymes ( p < 0.05). Overall, these results may suggest that the antihypertensive effect of FM-571 was linked to an improvement in the antioxidant status and SCFA production related to GM modulation.
No takes yet. Share an insight, caveat, or question.
Beltrán‐Barrientos et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: